Nutex Health Reports $11.8M Net Income for Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy NUTX?
Net income attributable to Nutex Health for the three months ended December 31, 2025 was $11.8M as compared to net income attributable to Nutex Health of $61.6M for the same period in 2024. The company attributes the $105.9M revenue decrease primarily to two items: a one-time $55.0M cumulative true-up of arbitration claims determined ineligible , with the associated catch-up reduced the number of active disputes compared to the same period in 2024 and contributed to lower net revenue for the quarter; and arbitration revenues of $69.0M relating to submissions during 3Q24 that were recorded in 4Q24. After considering the impact of the adjustments above, 4Q25 revenue would be $206.7M and 4Q24 revenue would be $188.6M, a revenue increase of $18.1M. "We are continuing to add to a record year with 82% revenue growth, Adjusted EBITDA attributable to Nutex Health of $259.6M, a 126.4% increase in gross profit and a record high cash balance of $185.6M," stated CFO Jon Bates. "Compared to 2024, we delivered improvements across nearly all key financial metrics. During 2025 and early 2026, we successfully opened three new micro-hospitals, further expanding our national footprint. In addition, both ER visits and inpatient admissions grew year over year, reflecting increased demand and strengthened operational performance," stated CEO Tom Vo. "Looking ahead, we are well positioned for continued growth through a balanced strategy that includes both de novo hospital development and increased patient volumes across our existing facilities."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUTX
Wall Street analysts forecast NUTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 134.590
Low
230.00
Averages
265.00
High
300.00
Current: 134.590
Low
230.00
Averages
265.00
High
300.00
About NUTX
Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates over 27 facilities in 12 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization, it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nutex Health NUTX Q1 2025 Earnings Transcript
See More
Nutex Health NUTX Q2 2025 Earnings Transcript
See More
Nutex Health Reports Q1 2026 Earnings Highlights
- Revenue Growth: Nutex Health reported total revenue of $216.5 million in Q1 2026, reflecting a 2.2% increase, with hospital division revenue at $207.6 million, indicating stable growth in the healthcare service sector.
- Net Income Increase: Net income rose to $46.8 million, showcasing improvements in cost control and operational efficiency, although adjusted EBITDA fell by 21% to $57.6 million, primarily due to the timing of IDR expense recognition.
- Share Repurchase Program: The company completed its inaugural $25 million share repurchase program and initiated a second program of the same size during the quarter, demonstrating management's confidence in future growth and commitment to capital returns.
- Hospital Development Strategy: The Board approved Nutex to directly invest in the development and construction of new hospital facilities, with each project estimated to cost between $20 million and $30 million, aiming to open three new hospitals in the second half of 2026 to enhance market competitiveness.
See More
Nutex Health Reports Significant Earnings Growth in Q1
- Significant Earnings Growth: Nutex Health reported Q1 earnings of $46.81 million, translating to $6.52 per share, a substantial increase from last year's $21.22 million and $3.33 per share, indicating a marked improvement in the company's profitability.
- Slight Revenue Increase: The company's revenue for the first quarter reached $216.49 million, up 2.2% from $211.79 million last year, reflecting a stable performance in the market despite the modest growth rate.
- Increased Market Confidence: The dual growth in earnings and revenue not only boosts investor confidence but may also attract more attention from potential investors, laying the groundwork for future capital operations and expansion.
- Strategic Development Potential: With enhanced profitability, Nutex Health is positioned to increase investments in new projects and market expansions, further solidifying its market position in the healthcare industry.
See More
Nutex Health Q1 Earnings Beat Expectations with Strong EPS
- Earnings Beat: Nutex Health reported a Q1 GAAP EPS of $6.52, exceeding expectations by $1.59, indicating strong profitability that may attract more investor interest.
- Revenue Miss: Despite a 2.2% year-over-year revenue increase to $216.49 million, the figure fell short of expectations by $11.31 million, reflecting competitive pressures that could impact future growth strategies.
- Positive Stock Reaction: Shares rose 3.2% in after-hours trading, suggesting a favorable investor response to the earnings report, which may enhance market confidence in the company's future performance.
- Stock Buyback Program: The company authorized a stock repurchase program of up to $25 million, aimed at enhancing shareholder value and stabilizing the stock price, demonstrating management's confidence in the company's future prospects.
See More
Nutex Health Reports Strong Q1 Financial Results with Significant Growth
- Revenue Growth: Nutex Health reported total revenue of $216.5 million for Q1 2026, reflecting a 2.3% increase year-over-year, indicating stable performance in its hospital division despite a complex market environment.
- Significant Net Income Increase: The company achieved a net income of $46.8 million in Q1 2026, representing a 120.6% increase compared to the same period in 2025, showcasing strong operational cash generation and effective execution of its growth strategy.
- Strong Cash Flow Position: Nutex reported operating cash flow of $75.5 million for the quarter, with cash and cash equivalents reaching $207.3 million, indicating a robust financial position that supports future expansion plans.
- Strategic Expansion Plans: The company aims to open three new hospitals in 2026, with the Board approving selective self-development through its real estate division, reflecting confidence in long-term growth opportunities.
See More
Nutex Health NUTX Q1 2025 Earnings Transcript
See More
Nutex Health NUTX Q2 2025 Earnings Transcript
See More
Nutex Health Reports Q1 2026 Earnings Highlights
- Revenue Growth: Nutex Health reported total revenue of $216.5 million in Q1 2026, reflecting a 2.2% increase, with hospital division revenue at $207.6 million, indicating stable growth in the healthcare service sector.
- Net Income Increase: Net income rose to $46.8 million, showcasing improvements in cost control and operational efficiency, although adjusted EBITDA fell by 21% to $57.6 million, primarily due to the timing of IDR expense recognition.
- Share Repurchase Program: The company completed its inaugural $25 million share repurchase program and initiated a second program of the same size during the quarter, demonstrating management's confidence in future growth and commitment to capital returns.
- Hospital Development Strategy: The Board approved Nutex to directly invest in the development and construction of new hospital facilities, with each project estimated to cost between $20 million and $30 million, aiming to open three new hospitals in the second half of 2026 to enhance market competitiveness.
See More
Nutex Health Reports Significant Earnings Growth in Q1
- Significant Earnings Growth: Nutex Health reported Q1 earnings of $46.81 million, translating to $6.52 per share, a substantial increase from last year's $21.22 million and $3.33 per share, indicating a marked improvement in the company's profitability.
- Slight Revenue Increase: The company's revenue for the first quarter reached $216.49 million, up 2.2% from $211.79 million last year, reflecting a stable performance in the market despite the modest growth rate.
- Increased Market Confidence: The dual growth in earnings and revenue not only boosts investor confidence but may also attract more attention from potential investors, laying the groundwork for future capital operations and expansion.
- Strategic Development Potential: With enhanced profitability, Nutex Health is positioned to increase investments in new projects and market expansions, further solidifying its market position in the healthcare industry.
See More
Nutex Health Q1 Earnings Beat Expectations with Strong EPS
- Earnings Beat: Nutex Health reported a Q1 GAAP EPS of $6.52, exceeding expectations by $1.59, indicating strong profitability that may attract more investor interest.
- Revenue Miss: Despite a 2.2% year-over-year revenue increase to $216.49 million, the figure fell short of expectations by $11.31 million, reflecting competitive pressures that could impact future growth strategies.
- Positive Stock Reaction: Shares rose 3.2% in after-hours trading, suggesting a favorable investor response to the earnings report, which may enhance market confidence in the company's future performance.
- Stock Buyback Program: The company authorized a stock repurchase program of up to $25 million, aimed at enhancing shareholder value and stabilizing the stock price, demonstrating management's confidence in the company's future prospects.
See More
Nutex Health Reports Strong Q1 Financial Results with Significant Growth
- Revenue Growth: Nutex Health reported total revenue of $216.5 million for Q1 2026, reflecting a 2.3% increase year-over-year, indicating stable performance in its hospital division despite a complex market environment.
- Significant Net Income Increase: The company achieved a net income of $46.8 million in Q1 2026, representing a 120.6% increase compared to the same period in 2025, showcasing strong operational cash generation and effective execution of its growth strategy.
- Strong Cash Flow Position: Nutex reported operating cash flow of $75.5 million for the quarter, with cash and cash equivalents reaching $207.3 million, indicating a robust financial position that supports future expansion plans.
- Strategic Expansion Plans: The company aims to open three new hospitals in 2026, with the Board approving selective self-development through its real estate division, reflecting confidence in long-term growth opportunities.
See More
